332 related articles for article (PubMed ID: 32468022)
1. Targeting cancer stem cells in cholangiocarcinoma (Review).
Mcgrath NA; Fu J; Gu SZ; Xie C
Int J Oncol; 2020 Aug; 57(2):397-408. PubMed ID: 32468022
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma.
Raggi C; Taddei ML; Sacco E; Navari N; Correnti M; Piombanti B; Pastore M; Campani C; Pranzini E; Iorio J; Lori G; Lottini T; Peano C; Cibella J; Lewinska M; Andersen JB; di Tommaso L; Viganò L; Di Maira G; Madiai S; Ramazzotti M; Orlandi I; Arcangeli A; Chiarugi P; Marra F
J Hepatol; 2021 Jun; 74(6):1373-1385. PubMed ID: 33484774
[TBL] [Abstract][Full Text] [Related]
3. The Expression of Yes-Associated Protein (YAP) Maintains Putative Cancer Stemness and Is Associated with Poor Prognosis in Intrahepatic Cholangiocarcinoma.
Sugiura K; Mishima T; Takano S; Yoshitomi H; Furukawa K; Takayashiki T; Kuboki S; Takada M; Miyazaki M; Ohtsuka M
Am J Pathol; 2019 Sep; 189(9):1863-1877. PubMed ID: 31220448
[TBL] [Abstract][Full Text] [Related]
4. Dysregulated YAP1/TAZ and TGF-β signaling mediate hepatocarcinogenesis in Mob1a/1b-deficient mice.
Nishio M; Sugimachi K; Goto H; Wang J; Morikawa T; Miyachi Y; Takano Y; Hikasa H; Itoh T; Suzuki SO; Kurihara H; Aishima S; Leask A; Sasaki T; Nakano T; Nishina H; Nishikawa Y; Sekido Y; Nakao K; Shin-Ya K; Mimori K; Suzuki A
Proc Natl Acad Sci U S A; 2016 Jan; 113(1):E71-80. PubMed ID: 26699479
[TBL] [Abstract][Full Text] [Related]
5. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
[TBL] [Abstract][Full Text] [Related]
6. Targeting interleukin 6 signaling by monoclonal antibody siltuximab on cholangiocarcinoma.
Nguyen MLT; Bui KC; Scholta T; Xing J; Bhuria V; Sipos B; Wilkens L; Nguyen Linh T; Velavan TP; Bozko P; Plentz RR
J Gastroenterol Hepatol; 2021 May; 36(5):1334-1345. PubMed ID: 33091158
[TBL] [Abstract][Full Text] [Related]
7. Multiple cellular origins and molecular evolution of intrahepatic cholangiocarcinoma.
Wei M; Lü L; Lin P; Chen Z; Quan Z; Tang Z
Cancer Lett; 2016 Sep; 379(2):253-61. PubMed ID: 26940139
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological Inhibition of Sonic Hedgehog Signaling Suppresses Tumor Development in a Murine Model of Intrahepatic Cholangiocarcinoma.
Cho K; Moon H; Seo SH; Ro SW; Kim BK
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948011
[TBL] [Abstract][Full Text] [Related]
9. Bioprinting of patient-derived in vitro intrahepatic cholangiocarcinoma tumor model: establishment, evaluation and anti-cancer drug testing.
Mao S; He J; Zhao Y; Liu T; Xie F; Yang H; Mao Y; Pang Y; Sun W
Biofabrication; 2020 Jul; 12(4):045014. PubMed ID: 32599574
[TBL] [Abstract][Full Text] [Related]
10. A Runaway PRH/HHEX-Notch3-Positive Feedback Loop Drives Cholangiocarcinoma and Determines Response to CDK4/6 Inhibition.
Kitchen P; Lee KY; Clark D; Lau N; Lertsuwan J; Sawasdichai A; Satayavivad J; Oltean S; Afford S; Gaston K; Jayaraman PS
Cancer Res; 2020 Feb; 80(4):757-770. PubMed ID: 31843982
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of hedgehog signaling attenuates carcinogenesis in vitro and increases necrosis of cholangiocellular carcinoma.
El Khatib M; Kalnytska A; Palagani V; Kossatz U; Manns MP; Malek NP; Wilkens L; Plentz RR
Hepatology; 2013 Mar; 57(3):1035-45. PubMed ID: 23172661
[TBL] [Abstract][Full Text] [Related]
12. Molecular genetics and targeted therapeutics in biliary tract carcinoma.
Marks EI; Yee NS
World J Gastroenterol; 2016 Jan; 22(4):1335-47. PubMed ID: 26819503
[TBL] [Abstract][Full Text] [Related]
13. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.
Saeed A; Park R; Al-Jumayli M; Al-Rajabi R; Sun W
Clin Colorectal Cancer; 2019 Jun; 18(2):81-90. PubMed ID: 30905548
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia induced Sonic Hedgehog signaling regulates cancer stemness, epithelial-to-mesenchymal transition and invasion in cholangiocarcinoma.
Bhuria V; Xing J; Scholta T; Bui KC; Nguyen MLT; Malek NP; Bozko P; Plentz RR
Exp Cell Res; 2019 Dec; 385(2):111671. PubMed ID: 31634481
[TBL] [Abstract][Full Text] [Related]
15. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
[TBL] [Abstract][Full Text] [Related]
16. Notch Signaling in Breast Cancer: A Role in Drug Resistance.
BeLow M; Osipo C
Cells; 2020 Sep; 9(10):. PubMed ID: 33003540
[TBL] [Abstract][Full Text] [Related]
17. Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications.
Wu HJ; Chu PY
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450710
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein.
Saikawa S; Kaji K; Nishimura N; Seki K; Sato S; Nakanishi K; Kitagawa K; Kawaratani H; Kitade M; Moriya K; Namisaki T; Mitoro A; Yoshiji H
Cancer Lett; 2018 Oct; 434():120-129. PubMed ID: 30031758
[TBL] [Abstract][Full Text] [Related]
19. Babaodan overcomes cisplatin resistance in cholangiocarcinoma via inhibiting YAP1.
Li J; Ma X; Xu F; Yan Y; Chen W
Pharm Biol; 2024 Dec; 62(1):314-325. PubMed ID: 38571483
[TBL] [Abstract][Full Text] [Related]
20. TAZ regulates cell proliferation and sensitivity to vitamin D3 in intrahepatic cholangiocarcinoma.
Xiao H; Tong R; Yang B; Lv Z; Du C; Peng C; Ding C; Cheng S; Zhou L; Xie H; Wu J; Zheng S
Cancer Lett; 2016 Oct; 381(2):370-9. PubMed ID: 27554639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
